For the past 100 years, the American Heart Association (AHA) has advocated for the growth of cardiovascular science. The annual AHA Scientific Sessions event brings together thousands of international colleagues to share the latest cardiovascular research and clinical practice advancements.
This year marks the 75th anniversary of the sessions, which will also be its first-ever hybrid event. On November 5—7, 2022, over 15,000 delegates will converge either in person in Chicago, IL, or virtually to review topics such as the latest heart failure guidelines, profiles in cardiovascular diseases, structural heart interventions, and more.
Brigham and Women’s Hospital will have a strong presence at this year’s event, with many experts from the Heart and Vascular Center set to present their research and evidence-driven clinical recommendations. The Brigham is proud to present alongside other cardiovascular experts from across the globe.
Late-Breaking and Featured Science
LBS.01: The Main Event: Changing Clinical Practice
Saturday, November 5 at 11:02 AM ET
- PROMINENT—A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of Cardiovascular Disease
LBS.05: Changing How We Prevent Cardiovascular and Renal Disease
Sunday, November 6 at 6:13 PM ET
- OCEAN(a)-DOSE—Reduction of Lipoprotein(a) With Small Interfering RNA: The Results of the Ocean(a)-DOSE Trial
LBS.07: Preventing Limb Loss Through Vascular Interventions and Venous Therapies
Monday, November 7 at 9:12 AM ET
- BEST-CLI (QOL)—Best Endovascular versus Best Surgical Therapy for Patients With Chronic Limb Threatening Ischemia—Quality of Life Analyses
Additional Brigham Participants
Ankeet Bhatt, MD, MBA
Impact of Coronavirus Disease-2019 on Participants in Delivery
The Epidemiology of Mechanical Complication After AMI: Has Anything Changed?
Evidence for a Unifying Pathomechanism for COVID’s Proclivity for Vascular Beds
One Brave Idea: Taking a Human First Approach to Treating and Preventing Disease
BEST-CLI (QOL)—Best Endovascular Versus Best Surgical Therapy for Patients With Chronic Limb Threatening Ischemia—Quality of Life Analyses
Reduction of Lipoprotein(a) With Small Interfering RNA: The Results of the Ocean(a)-DOSE Trial
Gregory Piazza, MD, MS
Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With COVID-19: Primary Results of the PREVENT-HD Randomized Clinical Trial
A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of Cardiovascular Disease
Usha B. Tedrow, MD, MS